Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Chugai
Pharma
Enspryng falls short of Roche's expectations in myasthenia gravis
Roche’s labeling Enspryng’s data as weak was a relief for other developers of biologics for gMG, such as Johnson & Johnson, UCB and argenx.
Angus Liu
Mar 21, 2024 11:28am
FDA oncology chief, Senate bill, Insilico—Fierce Pharma Asia
Apr 1, 2022 9:35am
Eisai-Biogen, US delisting, Zai Lab and more
Mar 18, 2022 9:10am
AstraZeneca pays Roche $775M to settle Ultomiris patent brawl
Mar 17, 2022 9:40am
Roche, AstraZeneca settle Ultomiris patent lawsuit
Feb 18, 2022 10:54am
Chugai claims Alexion used its patented tech to build Ultomiris
Nov 13, 2019 11:18am